Screening Project for Familial Hypercholesterolemia in Central, Southern, and Eastern Europe-ScreenPro

The ScreenPro FH Project started in 2014/2015. Based on the Czech MedPed experience the project was established for screening, diagnosis and treatment of FH patients in the region of Central, Eastern and Southern Europe.

• We started with 8 countries, now we are 20.
• We started with 70 centers, now we are 181 (other 40 in development).
• We started with 7500 patients in the local databases, now, they are 23 191.
• We started cooperation with patient´s organization in 8 countries (2017).
• We focus on education, screening and care of FH patients. Nowadays we are on the way from description of the situation to improvement in the treatment.

Severe FH Course “IDENTIFYING AND TREATING SEVERE FAMILIAL HYPERCHOLESTEROLEMIA” (Dubai, UAE, October 14-15, 2017)

The International Atherosclerosis Society (IAS), the Oman Society of Lipid and Atherosclerosis (OSLA), the Gulf Heart Association (GHA), and the Emirates Cardiac Society (ECS), are happy to make available to our readers some important documents related to the Course on Identifying and Treating Severe Familial Hypercholesterolemia which was held in Dubai, UAE on October 14-15, 2017. The Course was co-chaired by Profs. Raul Santos (President-Elect of IAS), Khalid Al-Rasadi (President, OSLA) and Wael Almahmeed (Board Member of GHA).

• Scientific Program & Abstracts
• Slide Library posted at www.athero.org/SevereFHCourse20171014 and at gulfheart.org/past-congresses.php

IAS SEVERE FH PANEL

IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”

The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.

To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.

Other FH activities

NEW DATA ON FAMILIAL HYPERCHOLESTEROLEMIA IN BRAZIL
For the abstract and full article please click here

LAUNCH E-LEARNING

Improving management through genetic testing for Familial Hypercholesterolaemia (FH)

This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:

• Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
• How and why to use genetic testing
• How to interpret results
• How to use cascade screening to identify related individuals at risk

NEWS FROM THE LIPID CLINICS in IRAQ

The success story deriving from the educational activities of the IAS and OSLA in the MENA Region continues. Thanks to the efforts of Dr. Mutaz Al-Sabah and his Iraqi colleagues at the moment 8 Lipid clinics have been established throughout the country:

1. Al-Diwaniya city
   Al-Diwaniya teaching hospital
    
   
   
   
2. Al-Sulaimaniya city
   Shorsh military teaching hospital
    
   
3. Al-Samawa city
   Al-Samawa teaching hospital
    
   
   
   
4. Salahaldeen city
   Balad teaching hospital
    
   
5. Al-Ramadi city
   Al-Ramadi teaching hospital
    
   
   
   
6. Al-Fallujah city
   Al-Fallujah teaching hospital
    
   
   
   
7. Erbil city
   Rizgary teaching hospital
    
   
   
   
8. Kirkuk city
   Kirkuk lipid clinic
   
   

The SAFEHEART Registry

Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice.

The International Atherosclerosis Society (IAS) and Oman Society of Lipid & Atherosclerosis (OSLA) are organizing the Fifth IAS-OSLA Course "Lipid Metabolism and Cardiovascular Risk" to be held in Muscat, Oman, on February 8-12, 2019.
As in 2015, 2016, 2017 and 2018, the aim of this Course is to increase the knowledge and experience of early- to mid-career, English-speaking practicing clinicians interested in the management of lipid disorders and will be restricted to 30 clinicians from the Middle East and North Africa (MENA) region who manage patients with lipid disorders.

Who can apply: Clinicians (including adult or pediatric cardiologists, endocrinologists, general practitioners, lipidologists, clinical biochemists) below the age of 40 years who are currently working at a hospital/university/other health institute in the MENA region.

More information will follow.